FDA gives accelerated approval to Genmab and Seagen's cervical cancer drug
Genmab and Seagen have received accelerated approval from the FDA for tisotumab vedotin, used to treat recurring or metastatic cervical cancer.
by marketwire, translated by catherine brett
Genmab and its partner Seagen have obtained accelerated approval for tisotumab vedotin, commercial name Tivdak, for the treatment of recurring or metastatic cervical cancer, from the US Food and Drug Administration (FDA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Horizon begins phase four clinical trial of Genmab drug
For subscribers
.jpg&w=384&q=75)
